Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Neoadjuvant Nivolumab in Glioblastoma Multiforme
NCT02550249Phase 2Completed
- Sponsor
- Universidad de Navarra
- Start
- Jun 2015
- Primary completion
- Mar 2017
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of nivolumab in glioblastoma multiforme (GBM), sponsored by Universidad de Navarra. Primary endpoint: Changes in percentage and level of expression of Programmed Death-Ligand 1 (PD-L1) at 4 weeks. Started Jun 2015; status: completed.
02
Drugs
03
Conditions
glioblastoma multiforme (GBM)
Beyond the preview
Go deeper on NCT02550249.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02550249.